Abstract: The purpose of the present invention is to provide a method for producing 6-bromo-3-hydroxy-2-pyrazinecarboxamide in which the content ratio of impurities is reduced. This production method includes a step of obtaining 6-bromo-3-hydroxy-2-pyrazinecarboxamide crystal having diffraction angles expressed in degrees 2? of 5.5, 20.1, 23.7, 26.7, 27.5, and 28.1° and/or diffraction angles expressed in degrees 2? of 7.1, 21.4, 25.2, 25.7, 27.1, and 28.8° in powder X-ray diffraction.

Abstract: Provided are a drug recognizing apparatus, a drug recognizing method, and a drug recognizing program capable of enhancing robustness of a master image in a case where a drug is recognized. The drug recognizing apparatus includes an illumination unit that illuminates a drug; an imaging unit that images the illuminated drug; a storage unit that stores a master image for each drug type; a drug position acquiring unit that acquires a position of the drug on the basis of a captured image obtained by the imaging unit; a master image generating unit that generates the master image from a drug area in the captured image; an updating determination unit that determines whether to update the master image on the basis of the position of the drug acquired by the drug position acquiring unit; and a registration unit that registers the master image in the storage unit in a case where it is determined that the master image is to be updated.

Abstract: An object of the present invention is to provide a composition for external use having an improved skin permeability of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof. The present invention provides a composition for external use comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, one or more solvents selected from the group consisting of alcohols, sulfoxides and amides, and a permeation enhancer.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof at a high concentration, with a characteristic bitter taste masked, and a manufacturing method thereof. The present invention provides a pharmaceutical composition comprising fine granules having a core comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a binder; and a polymer layer with which a surface of the core is coated, wherein the fine granules have a roundness of 0.8 or more and a content of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof in the fine granules is 30 to 90% by mass.

Abstract: Provided is a medicinal composition characterized by comprising an alkyl ether derivative represented by general formula [1] [wherein: R1 and R2 are the same or different and represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, etc.; R3 represents an optionally protected hydroxyl group, etc.; and m and n are the same or different and represent an integer of 1 to 6] or a salt thereof. The medicinal composition according to the present invention is useful as a post nerve injury rehabilitation effect-enhancing agent.

Abstract: The object of the present invention is to provide a solid pharmaceutical composition in which both the pre-bitter taste and the post-bitter taste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof are suppressed. The present invention provides a solid pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and a compound having at least one hydrocarbon group having 8 to 18 carbon atoms and a sulfo group or a salt thereof.

Abstract: An object of the present invention is to provide a solid pharmaceutical composition which suppresses the characteristic bitter taste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and has a good storage stability of the-aforementioned compound or a salt thereof. The present invention provides a solid pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and a carboxylic acid whose solubility in water at 25° C. is 50 g/100 g H2O or less, wherein pH of a solution obtained when the solid pharmaceutical composition is dissolved or suspended in a 10 mmol/L KCl solution such that 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof is 1 mg/mL or 8.96 mg/mL is 4.8 or less.

Abstract: It is an object of the present invention to provide an antitumor agent, which is further excellent as a treatment agent used in the prevention and/or therapy of tumor associated with a bromodomain, and also to provide a bromodomain inhibitor, which is useful as a treatment agent for diseases or states associated with a bromodomain. An antitumor agent and a bromodomain inhibitor, comprising a compound represented by the following formula, have an excellent bromodomain inhibitory activity and are useful as treatment agents in the prevention and/or therapy of tumor associated with a bromodomain, and the like: wherein R1 represents a C1-6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a halogen atom, etc.; Z1, Z2 and Z3 each represent CH, etc.; X1 represents CONH, etc.; Ring A represents a phenyl group, etc.; R4 represents a halogen atom, etc.; and m represents an integer from 0 to 5.

Abstract: Provided is a transport device which can perform easily thermal storage temperature controlling treatment of the thermal storage material even at a cell transport destination. The transport device of the present invention includes: a thermally insulated container that has a cylindrical shape and a bottom, a thermal storage material disposed along the inner circumferential surface of the thermally insulated container, and a temperature control unit that is detachably fitted on the thermally insulated container and is for performing thermal storage temperature controlling treatment on the thermal storage material, wherein the temperature controlling unit comprises a heat transferring body for performing the thermal storage temperature control processing on the thermal storage material when the unit is fitted on the thermally insulated container, and a storage space formed inside the heat-transferring body for storing a stored object so that the object can be freely put in and taken out.

Abstract: The purpose of the present invention is to provide a method for producing 6-bromo-3-hydroxy-2-pyrazinecarboxamide in which the content ratio of impurities is reduced. This production method includes a step of obtaining 6-bromo-3-hydroxy-2-pyrazinecarboxamide crystal having diffraction angles expressed in degrees 2? of 5.5, 20.1, 23.7, 26.7, 27.5, and 28.1° and/or diffraction angles expressed in degrees 2? of 7.1, 21.4, 25.2, 25.7, 27.1, and 28.8° in powder X-ray diffraction.

Abstract: Provided is a composition containing a buffer to be used at the time of labeling of a chelated targeting agent with 90Y, 153Sm, 165Dy, 165Er, 166Ho, or 177Lu. At least one kind of buffer selected from the group consisting of benzoic acid, maleic acid, fumaric acid, succinic acid, and salts thereof is incorporated in a composition containing a chelated targeting agent.

Abstract: An anti-hepatitis B virus agent comprising a compound represented by general formula [1], wherein R1 represents an aryl group, which may be substituted, or the like; R2 represents an aryl group, which may be substituted, or the like; and R3 represents a hydrogen atom or the like; or a salt thereof.

Abstract: The present invention provides a transport container comprising; a first container having a first inner wall with a storage space for storing a transported object and a first outer wall provided on the outside of the first inner wall so as to form, with the first inner wall, a vacuum space therebetween; a first lid that is heat-insulating and is for removably sealing a first opening of the first container; a second container having a second inner wall with a space for storing the first container and the first lid and a second outer wall provided on the outside of the second inner wall so as to form, with the second inner wall, a vacuum space therebetween; a second lid that is heat-insulating and is for removably sealing a second opening of the second container; and a heat storage material for surrounding the transported object inside the storage space.

Abstract: Provided is a method for industrially producing 5-(bromomethyl)-1-benzothiophene. The production method according to the present invention comprises: (1) a step for introducing 5-methyl-1-benzothiophene, a brominating agent, and a solvent into a reactor; (2) a step for emitting light having a wavelength range of 200-780 nm inside the reactor; and (3) a step for recovering 5-(bromomethyl)-1-benzothiophene from the reactor.

Abstract: The purpose of the present invention is to provide a method for producing 6-bromo-3-hydroxy-2-pyrazinecarboxamide in which the content ratio of impurities is reduced. This production method includes a step of obtaining 6-bromo-3-hydroxy-2-pyrazinecarboxamide crystal having diffraction angles expressed in degrees 2? of 5.5, 20.1, 23.7, 26.7, 27.5, and 28.1° and/or diffraction angles expressed in degrees 2? of 7.1, 21.4, 25.2, 25.7, 27.1, and 28.8° in powder X-ray diffraction.

Abstract: A sigma receptor-binding agent, which comprises an alkyl ether derivative represented by formula [1] or a salt thereof is provided. wherein R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, or the like; R3 represents an optionally protected hydroxyl group or the like; m and n, which are the same or different, each represent an integer of 1 to 6.

Abstract: Crystals of 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1H-indol-5-yl)amino)nicotinic acid having diffraction peaks at diffraction angles (2?) of 12.2±0.2, 17.2±0.2, 19.4±0.2, 24.1±0.2, and 27.1±0.2° or diffraction angles (2?) of 12.9±0.2, 15.5±0.2, 21.2±0.2, 21.7±0.2, and 25.9±0.2° in powder x-ray diffraction have excellent stability, are easy to handle, and are useful as a drug substance of pharmaceuticals to be used in treatments such as the prevention or treatment of diseases involving keratinocyte hyperproliferation.